Synthesis and Antiproliferative Evaluation of 2-Deoxy-N-glycosylbenzotriazoles/imidazoles.

A series of 2-deoxy-2-iodo-α-d-mannopyranosylbenzotriazoles was synthesized using the benzyl, 4,6-benzylidene and acetyl protected D-glucal in the presence of N-iodosuccinimide (NIS). Subsequent removal of the iodine at the C-2 position using tributyltin hydride under free radical conditions afforded the 2-deoxy-α-d-glucopyranosylbenzotriazoles in moderate to high yields. This method was extended to the preparation of substituted 2-deoxy-ß-d-glucopyranosylimidazoles as well. The stereoselectivity of the addition reaction and the effect of the protecting group and temperature on anomer distribution of the benzotriazole series were also investigated. The anticancer properties of the newly synthesized compounds were evaluated in a series of viability studies using HeLa (human cervical adenocarcinoma), human breast and lung cancer cell lines. The N-[3,4,6-tri-O-benzyl-2-deoxy-α-d-glucopyranosyl]-1H-benzotriazole and the N-[3,4,6-tri-O-acetyl-2-deoxy-α-d-glucopyranosyl]-2H-benzotriazole were found to be the most potent cancer cell inhibitors at 20 µM concentrations across all four cell lines.

Biobanks and biomarker research in cardiovascular disease.

PURPOSE: The purpose of this article is to describe biobank processes and the sociocultural and nursing challenges of these processes. The article will present ways that thinking genetically can challenge cardiovascular nurses and help in the development of biobanks for cardiovascular research. It will emphasize the importance of the contributions of nursing to the development of biobanks and biobanking research. CONCLUSIONS: The influence of cardiovascular nurses on the development of biobanks for research in cardiovascular disease will result in accelerated discoveries that will lead to innovative, safe, effective therapeutics (translational research and personalized healthcare). The challenge is to educate and encourage clinicians to think genetically and use biobanks for research.

Peripheral vascular reactivity in patients with pulsatile vs axial flow left ventricular assist device support.

BACKGROUND: Left ventricular assist devices (LVADs) are either pulsatile or axial flow devices. The latter can be operated at a low-speed setting to allow pulsatility or at a high-speed setting to create continuous flow. The purpose of this study was to compare the effect of continuous flow and pulsatile flow on peripheral vascular reactivity. METHODS: Twenty consecutive patients were divided into two groups based on the type of LVAD they received. Ten patients had a pulsatile flow LVAD, and 10 had an axial flow LVAD. For the purpose of the study protocol, the axial flow devices were operated at a high speed to ensure continuous flow. The patients' peripheral artery vasoreactivity was assessed with an ultrasound vascular transducer that measured flow-mediated dilation (FMD). RESULTS: The FMD of the patients supported with pulsatile flow (15.6 +/- 5%) was higher than the FMD of the patients supported with temporary continuous flow (1.8 +/- 3%). The difference was statistically significant (p < 0.0001). CONCLUSIONS: Pulsatile flow is associated with a better peripheral vascular reactivity than continuous flow. Patients supported by axial flow devices should be kept on the lowest speed setting to allow maximum pulsatility.